Adjuvant Nivolumab-Ipilimumab Failed to Improve DFS in Renal Cell Carcinoma
Nivolumab plus ipilimumab did not prolong disease-free survival, and 43% of patients discontinued treatment due to toxicities.
All articles by Andrea S. Blevins Primeau, PhD, MBA
COSMIC-313: Triplet Prolongs PFS vs Doublet in Renal Cell Carcinoma
The PFS benefit was driven primarily by patients with intermediate-risk disease.
MRI-Based Assessment May Eliminate Need for TURBT in Muscle-Invasive Bladder Cancer
MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.
Longer Course of ADT With Postop Radiotherapy Improves Metastasis-Free Survival in Prostate Cancer
Adding a longer course of androgen deprivation therapy to postoperative radiotherapy may prolong metastasis-free survival in patients with prostate cancer.
Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...